ZIOPHARM Oncology Inc logo

ZIOP - ZIOPHARM Oncology Inc Share Price

$4.93 -0.1  -2.8%

Last Trade - 13/12/19

Sector
Healthcare
Size
Mid Cap
Market Cap £697.3m
Enterprise Value £630.1m
Revenue £n/a
Position in Universe 2490th / 6391
Bullish
Bearish
Unlock ZIOP Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ZIOP Revenue Unlock ZIOP Revenue

Net Income

ZIOP Net Income Unlock ZIOP Revenue

Normalised EPS

ZIOP Normalised EPS Unlock ZIOP Revenue

PE Ratio Range

ZIOP PE Ratio Range Unlock ZIOP Revenue

Dividend Yield Range

ZIOP Dividend Yield Range Unlock ZIOP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ZIOP EPS Forecasts Unlock ZIOP Revenue
Profile Summary

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated May 16, 2005
Public Since March 15, 2002
No. of Shareholders: 28,718
No. of Employees: 48
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 181,030,020
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ZIOP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ZIOP
Upcoming Events for ZIOP
Similar to ZIOP
© Stockopedia 2019, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.